Literature DB >> 7650803

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

S A Grover1, L Coupal, X P Hu.   

Abstract

OBJECTIVE: To assess the accuracy of lipid screening strategies to identify individuals at increased risk of coronary heart disease mortality. PATIENTS: The 15% random sample of adults recruited into the Lipid Research Clinic Prevalence and Follow-up Studies, which included 3678 men and women aged 35 to 74 years. Total plasma cholesterol levels, lipoprotein fractions, and other coronary risk factors at study entry were compared with subsequent coronary heart disease mortality (mean follow-up, 12.2 years). MAIN OUTCOME MEASURES: The areas under receiver operating characteristic curves for blood lipids, lipid ratios, the screening guidelines proposed by the National National Cholesterol Education Program, those of the Canadian Consensus Conference on Cholesterol, and a coronary risk model that used Framingham data. MAIN
RESULTS: The current National Cholesterol Education Program guidelines (area under the curve, 0.74) were significantly (P = .03) more accurate than the old National Cholesterol Education Program guidelines (area, 0.72). The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level (area, 0.72) was as accurate as current National Cholesterol Education Program guidelines. The coronary risk model (area, 0.85) was superior (P < .003) to all other screening maneuvers. Compared with the current National Cholesterol Education Program guidelines, the risk model demonstrated superior test sensitivity (70% vs 45%) with only slightly reduced specificity (82% vs 86%).
CONCLUSION: The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level is as accurate as current American screening guidelines. Future guidelines should better incorporate high-density lipoprotein cholesterol levels and nonlipid risk factors to target high-risk individuals accurately.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650803

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

1.  Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Authors:  D M Pickin; C J McCabe; L E Ramsay; N Payne; I U Haq; W W Yeo; P R Jackson
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

2.  Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Authors:  E J Wallis; L E Ramsay; I Ul Haq; P Ghahramani; P R Jackson; K Rowland-Yeo; W W Yeo
Journal:  BMJ       Date:  2000-03-11

3.  Estimating cardiovascular risk for primary prevention: outstanding questions for primary care.

Authors:  J Robson; K Boomla; B Hart; G Feder
Journal:  BMJ       Date:  2000-03-11

Review 4.  The physiology of lipoproteins.

Authors:  Thomas N Tulenko; Anne E Sumner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

5.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

Authors:  I U Haq; L E Ramsay; W W Yeo; P R Jackson; E J Wallis
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

Review 6.  Cardiovascular and coronary risk estimation in hypertension management.

Authors:  Erica J Wallis; Lawrence E Ramsay; Peter R Jackson
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

7.  Improved comorbidity adjustment for predicting mortality in Medicare populations.

Authors:  Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Robert J Glynn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

8.  Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials.

Authors:  G V Robinson; J C T Pepperell; H C Segal; R J O Davies; J R Stradling
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

9.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

10.  Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy.

Authors:  Uli C Broedl; Hans-Christian Geiss; Klaus G Parhofer
Journal:  J Gen Intern Med       Date:  2003-03       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.